Skip to main content
    L

    Ligand Pharmaceuticals Incorporated (LGND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $301.71
    -7.08 (-2.29%)

    Market Cap: $6.18B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ligand Pharmaceuticals Incorporated (LGND) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ligand Pharmaceuticals (LGND) trades at 66.5x trailing earnings and 23.7x sales. Its P/E of 66.5x is above its 5-year median of 17.9x. Its forward P/E is 25.1x. The median P/E across 3 similar companies is 87.2x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 164.9% higher over the next year. Its free cash flow yield is 1.5%.

    MultipleValue
    P/E (trailing)66.5x
    Forward P/E25.1x
    Price to sales23.7x
    Price to book6.3x
    EV/EBITDA189.1x
    Price to FCF66.5x
    EV/FCF78.3x
    PEG1.5
    FCF yield1.5%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 179.4% above 23.8x, its P/S is 76.9% above 13.4x and its P/B is 142.3% above 2.6x.

    MultipleCurrent5-year median10-year median
    P/E66.5x17.9x23.8x
    P/S23.7x10.7x13.4x
    P/B6.3x2.4x2.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 108 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 11.7x in 2023 to 42.3x in 2017.

    Year endPriceP/EP/SP/B
    2025$189.0727.9x14.0x3.9x
    2024$107.1518.8x11.7x2.4x
    2023$71.4211.7x9.4x1.8x
    2022$66.8015.0x5.7x1.9x
    2021$154.4624.1x10.6x3.1x
    2020$99.4521.9x9.9x2.3x
    2019$104.2934.3x16.6x2.3x
    2018$135.7019.0xN/A5.1x
    2017$136.9342.3x20.4x6.9x
    2016$101.6130.4x19.4x5.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About LGND

    What is LGND's forward P/E ratio?

    Ligand Pharmaceuticals has a forward P/E ratio of 25.1x.

    Is LGND stock overvalued?

    GNG's valuation label for LGND is Overvalued. Its P/E of 66.5x compares with a median of 87.2x across 3 similar companies.

    What is LGND's price to sales ratio?

    Ligand Pharmaceuticals has a price to sales ratio of 23.7x.

    What is Ligand Pharmaceuticals's average P/E ratio over 5 years?

    Ligand Pharmaceuticals's median P/E over the last 5 years is 17.9x, from 60 month-end values through Oct 2026.

    What is LGND's PEG ratio?

    Ligand Pharmaceuticals has a PEG ratio of 1.5.